Get the app
Ehsan Rahimy
Director of Vitro-Retinal Diseases at the Palo Alto Medical Foundation. Corresponding author of the manuscript on Mammalian Target Rapamycin Inhibition as a Therapeutic Target for Prevention of Proliferative Vitreoretinopathy.
Best podcasts with Ehsan Rahimy
Ranked by the Snipd community
Aug 7, 2025
• 18min
JAMA Ophthalmology : Mammalian Target Rapamycin Inhibition for Proliferative Vitreoretinopathy
chevron_right
In this engaging discussion, Ehsan Rahimy, a leading expert in vitreoretinal diseases, sheds light on the promising role of mTOR inhibitors in preventing proliferative vitreoretinopathy (PVR). He dives into the significance of mTOR as a cellular regulator and its implications for retinal health. Rahimy reviews remarkable data showcasing a 40% reduction in retinal detachment risks through mTOR therapies. Plus, he emphasizes the need for randomized clinical trials to validate excitement in innovative treatments, setting a hopeful tone for future retinal surgeries.
The AI-powered Podcast Player
Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
Get the app
